Therefore, we performed two-sample MR analysis in this study to test the association of lipid‐lowering drugs (HMGCR inhibitiors, PCSK9 inhibitiors, and NPC1L1 inhibitior) with COVID-19 outcomes (susceptibility, hospitalization and very severe disease). This evidence concerns the gene HMGCR and COVID-19.